Comparative Study Behavioural brain research. 2008 Dec 12;194(2):152-61. doi: 10.1016/j.bbr.2008.06.035 Q22.32025

A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs

一种新型腺苷A1和A2A受体拮抗剂ASP5854可改善MPTP致狨猴的运动障碍：与现有抗帕金森病药物比较研究 翻译改进

作者单位 +展开

DOI: 10.1016/j.bbr.2008.06.035 PMID: 18657577

摘要 Ai翻译

Copyright © Behavioural brain research. 中文内容为AI机器翻译，仅供参考！

相关内容

• In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease

  帕金森病动物模型中腺苷A2A / A1受体双重拮抗剂的体内特征研究

  Brian C Shook et al.

  Journal of medicinal chemistry. 2010 Nov 25;53(22):8104-15.

• Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition

  新型强效腺苷A1和A2A受体双拮抗剂ASP5854在帕金森病和认知模型中的药理学特征研究

  Takuma Mihara et al.

  The Journal of pharmacology and experimental therapeutics. 2007 Nov;323(2):708-19.

• Discovery of novel 1,3,5-triazine as adenosine A2A receptor antagonist for benefit in Parkinson's disease

  新型三嗪类腺苷A2A受体拮抗剂用于治疗帕金森病的研究发现

  Anup Masih et al.

  Journal of biochemical and molecular toxicology. 2021 Mar;35(3):e22659.

• Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson's disease

  苍白球同步振荡活动与帕金森病患者的运动功能障碍相关性研究

  Wolf-Julian Neumann et al.

  Movement disorders : official journal of the Movement Disorder Society. 2016 Nov;31(11):1748-1751.

• Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients

  运动障碍影响帕金森病患者的Farnsworth-Munsell 100色盘检查错误得分

  Thomas Müller et al.

  Journal of the neurological sciences. 2003 Sep 15;213(1-2):61-5.

• The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists

  新型腺苷受体(A2A)拮抗剂的发现和合成

  Julius J Matasi et al.

  Bioorganic & medicinal chemistry letters. 2005 Mar 1;15(5):1333-6.

• Angiotensin converting enzyme inhibition prevents trophic and hypertensive effects of an antagonist of adenosine receptors

  血管紧张素转换酶抑制可防止腺苷受体拮抗剂的营养和高血压效应

  Teresa Sousa

  European journal of pharmacology. 2002 Apr 19;441(1-2):99-104.

• Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists

  具有高选择性和较强活性的人A3腺苷受体拮抗剂并[4，3-e][1，5-c]嘧啶衍生物研究进展

  P G Baraldi et al.

  Journal of medicinal chemistry. 1999 Nov 4;42(22):4473-8.

• Synthesis and structure-activity relationships of 4-cycloalkylamino-1, 2, 4-triazolo[4, 3-a]quinoxalin-1- one derivatives as A1 and A3 adenosine receptor antagonists

  一类新型的A₁和A₃腺苷受体拮抗剂——4-环烷基氨基-1,2,4-三唑并[4,3-a]喹喔啉-1-酮类化合物的设计、合成及构效关系研究

  Vittoria Colotta et al.

  Archiv der Pharmazie. 2004 Jan;337(1):35-41.